Change of Adviser

Allergy Therapeutics PLC
14 November 2005

14 November 2005

                            Allergy Therapeutics plc

                          CHANGE OF ADVISER AND BROKER

Following completion of the acquisition of the UK Equity Capital Markets
division of Robert W Baird Limited by Bridgewell Securities Limited, Allergy
Therapeutics plc is pleased to announce the appointment of Bridgewell Securities
Limited as Nominated Adviser and Broker with immediate effect.

For further information please contact:

Allergy Therapeutics                 01903 844720
Keith Carter, Chief Executive

Bridgewell Securities Limited       020 7003 3000
Shaun Dobson, Managing Director


                      This information is provided by RNS
            The company news service from the London Stock Exchange